|Mr. Jean-Christophe Tellier||Chief Exec. Officer and Exec. Director||3.07M||N/A||1959|
|Mr. Detlef Thielgen||Chief Financial Officer and Exec. VP||N/A||N/A||1960|
|Ms. Anna S. Richo||Exec. VP and Gen. Counsel||N/A||N/A||1960|
|Dr. Bharat Tewarie||Chief Marketing Officer and Exec. VP||N/A||N/A||1961|
|Prof. Iris Löw-Friedrich||Chief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VP||N/A||N/A||1960|
UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and Crohn's disease; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy. Its product pipeline includes Evenity for the treatment of osteoporosis; bimekizumab for psoriasis, psoriatic arthritis, and ankylosing spondylitis diseases; dapirolizumab pegol for systemic lupus erythematosus; padsevonil for highly drug resistant epilepsy; seletalisib for Sjögren's syndrome; rozanolixizumab for immune thrombocytopenia; UCB4144/VR942 for asthma; UCB6673, UCB7858, and UCB0159 for the treatment of neurology; and UCB3491 and UCB0599 for bone treatment. UCB SA was founded in 1928 and is based in Brussels, Belgium.
UCB SA’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 5.